Nordiet diet tested as a natural way to ease IBD symptoms
NCT ID NCT07389161
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether a Mediterranean-like diet called Nordiet can improve gut health and reduce inflammation in 160 teens and adults with Crohn's disease or ulcerative colitis. Participants will follow the diet for four weeks while researchers check changes in gut bacteria, disease activity, and quality of life. The goal is to see if diet alone can help manage IBD without changing other treatments.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Mediterranean-like diet (Nordiet)
- What this could lead to
- If it works, this could point toward a simple dietary approach to help manage IBD symptoms and reduce inflammation.
- What could go wrong
- This is a small, early-phase study with no control group, so results may not be conclusive. Diet changes alone may not be enough for moderate-to-severe disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 160 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2026
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 35 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * IBD, i.e., Mb Crohn or ulcerrative colitis * Moderatively active disease (calprotectin 200-600) Exclusion Criteria: * Proctitis alone * Inactive disease * Severe flare up requiring in-patient care * Planned change of treatment * Antibiotic treatment during the last month * Pregnancy * Inability to understand Swedish * Multimorbidity
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MB Crohn are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Skåne University Hospital
RECRUITINGMalmö, 21428, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Triple-Pronged attack on gut inflammation put to the test
- Two biologics go head to head in ulcerative colitis
- New drug ATTO-1091 put to the test for safety in ulcerative colitis
- Antiparasitic drug tested as new weapon against ulcerative colitis
- Could your Donor's gut bacteria decide whether a stool transplant works?
- Exercise as a potential remedy for IBD-related fatigue